Wai Har Ng | Drug Discovery and Development | Best Researcher Award

Ms. Wai Har Ng | Drug Discovery and Development | Best Researcher Award

Senior Research Associate at National Cancer Centre Singapore | Singapore

Ms. Wai Har Ng is a Senior Research Associate at the National Cancer Centre Singapore with over two decades of experience in cancer biology and translational research. His scientific journey spans genetic engineering, molecular oncology, and personalized therapeutics, with a strong focus on hepatocellular carcinoma, peritoneal carcinomatosis, and colorectal cancer. A dynamic contributor to national research consortiums, Ng WH has authored numerous high-impact publications and excels in molecular, cellular, and in vivo experimental platforms. Known for his collaborative spirit, he plays a pivotal role in mentoring, protocol development, and driving clinical translation in cancer therapy through precision medicine and molecular marker discovery.

Publication Profile 

Scopus

Education

Ms. Wai Har Ng obtained a Master of Science in Genetic Engineering from University Putra Malaysia (2005), where his dissertation focused on gene expression profiling of oil palm root systems using EST and microarray technology. He earned his Bachelor of Science in Biotechnology (2000) from the same university, working on Arabidopsis root transformation. His foundational education was completed at Chong Hwa Independent High School, Kuala Lumpur, from 1990–2000, with certifications including STPM, SPM, and SRP. His early academic training at SRJK (C) Tsun Jin laid the groundwork for a career defined by scientific curiosity, discipline, and innovation in molecular biosciences.

Experience 

Ms. Wai Har Ng currently serves as a Senior Research Associate at the National Cancer Centre Singapore (2017–present), where he spearheads research on molecular therapeutics and biomarker discovery. He previously worked as a Research Officer and Research Associate at the same institute (2004–2017), contributing to groundbreaking oncology studies. Earlier, he served at the Malaysian Agricultural Research & Development Institute (MARDI) from 2003–2004. His academic skillset spans molecular biology, proteomics, imaging, animal studies, and lab management. Proficient in BSL2 safety, grant collaboration, and multidisciplinary research, he plays a key role in mentoring, lab operations, and translational biomedical research.

Awards 

While specific awards were not listed, Ng WH’s achievements are evident through his prolific publication record in high-impact journals, participation in national research consortia like the Singapore Peritoneal Oncology Study (SPOS) and Singapore Gastric Cancer Consortium (SGCC), and recognition as a core contributor to precision oncology research. His co-authorship on influential studies in Scientific Reports, Cell Reports Medicine, and International Journal of Molecular Sciences demonstrates academic recognition and leadership. His technical versatility and mentorship roles further highlight his contribution to national cancer research excellence. If formal awards were earned, these would further bolster his already commendable profile.

Research Focus 

Ng WH focuses on translational cancer research with emphasis on hepatocellular carcinoma, colorectal cancer, peritoneal carcinomatosis, and liposarcoma. His work integrates drug synergy, molecular profiling, biomarker discovery, and machine learning to optimize personalized cancer therapies. He is proficient in CRISPR, ddPCR, organoid modeling, xenografts, and immunofluorescence microscopy. A key area includes developing predictive molecular signatures for chemotherapy response and leveraging advanced imaging to study tumor behavior. With over 13 peer-reviewed publications, Ng WH bridges basic science and clinical application, contributing to a future where cancer treatment is personalized, precise, and highly effective.

Publication Top Notes

Title: Vinorelbine Improves the Efficacy of Sorafenib against Hepatocellular Carcinoma: A Promising Therapeutic Approach
Journal: International Journal of Molecular Sciences
Year: 2024
Citations: 5

Title: Everolimus Acts in Synergy with Vinorelbine to Suppress the Growth of Hepatocellular Carcinoma
Journal: International Journal of Molecular Sciences
Year: 2024
Citations: 4

Conclusion

Ms. Wai Har Ng is a highly competent and experienced researcher whose scientific contributions have advanced the field of cancer biology and therapeutics. Her technical mastery, consistent publication output, and collaborative involvement with national research consortia highlight her as a valuable asset to the research community. With increased visibility through leadership roles in publications and funding acquisition, she would stand out even more prominently. She is a strong and deserving candidate for the Best Researcher Award, given her sustained excellence, innovation, and impact in translational cancer research.

Hui Xiao | Drug Discovery and Development | Pharmaceutical Innovation Achievement Award

Hui Xiao | Drug Discovery and Development | Pharmaceutical Innovation Achievement Award

Dr Hui Xiao,regeneron,United States

Dr. Hui Xiao 🧪🔬 is a distinguished scientist specializing in biochemistry, structural biology, and mass spectrometry. With a strong focus on microtubule dynamics, protein interactions, and drug mechanisms, he has made significant contributions to understanding cellular processes. As a co-first author and lead researcher, his work has been published in esteemed journals like J. Mol. Biol., Biochemistry, and J. Biol. Chem.. His expertise spans hydrogen-deuterium exchange, proteomics, and molecular stabilization studies. Dr. Xiao’s research has advanced drug discovery, particularly in cancer therapeutics and protein biochemistry. 📚🔍 His innovative approaches continue to impact biomedical sciences globally. 🌍✨

Publication Profile

Scopus

Education

Dr. Hui Xiao 🎓 holds a Ph.D. in Analytical Chemistry from the University of Massachusetts, Amherst (2005) and a degree in Applied Chemistry from Peking University, China (1992). Currently serving as an Associate Director at Regeneron Pharmaceuticals 🏢, he specializes in protein characterization using mass spectrometry. With over a decade at Regeneron, he has progressed through roles as a Senior Staff Scientist and Staff Scientist. Previously, he held academic positions at Albert Einstein College of Medicine 🧬, advancing from Instructor to Research Associate Professor. His expertise spans analytical chemistry, protein analysis, and therapeutic protein research, making significant contributions to biomedical science. 🔬

Professional Impact

Dr. Hui Xiao 🎓 is a distinguished scientist with over 20 years of experience in academia and the biotechnology industry. Currently, he serves as an Associate Director of Analytical Chemistry at Regeneron Pharmaceuticals 🏢, a leading biotech company. His expertise lies in mass spectrometry applications for protein characterization 🔬, contributing to advancements in therapeutic development. Before joining Regeneron, Dr. Xiao held esteemed faculty positions at Albert Einstein College of Medicine 🧬, progressing from Instructor to Research Associate Professor. His extensive research and leadership have played a crucial role in bridging analytical chemistry with biopharmaceutical innovation, impacting drug discovery and development. 🚀

Scientific Contributions

Dr. Hui Xiao 🎓 is a leading expert in protein-ligand interactions, structural proteomics, and therapeutic protein analysis 🔬. His pioneering work includes the application of hydrogen-deuterium exchange mass spectrometry (HDX-MS) for epitope mapping 🧩 and microtubule stabilization research. With a deep focus on drug characterization and regulatory sciences, his contributions have significantly advanced biopharmaceutical development 💊. His expertise in mass spectrometry-driven protein analysis has helped enhance the understanding of molecular mechanisms, improving therapeutic strategies. Through innovation and research, Dr. Xiao continues to play a vital role in shaping the future of biopharmaceutical science and drug discovery. 🚀

Potential Considerations

Dr. Hui Xiao 🎓 is a renowned expert in analytical and protein chemistry, with groundbreaking work in epitope mapping and protein characterization 🔬. While his contributions significantly impact drug development, the Pharmaceutical Innovation Achievement Award 🏆 may prioritize direct advancements in drug discovery and novel pharmaceutical interventions 💊. His research has important regulatory and therapeutic implications, but highlighting specific drug innovations or regulatory breakthroughs he has led would further strengthen his case. By showcasing his role in pioneering pharmaceutical advancements, Dr. Xiao’s influence in shaping modern biopharmaceutical science can be fully recognized and appreciated. 🚀

Research Focus

Dr. Hui Xiao’s research primarily focuses on analytical chemistry 🧪, particularly in the quantitative analysis of biomolecules 🧬 using advanced mass spectrometry techniques ⚖️. His work involves CRISPR sgRNA modification analysis 🧬🔬 and the development of LC-MS-based assays for biological therapeutics 💊. He specializes in phosphorothioate isomer detection 🔄 and liquid chromatography-multiple reaction monitoring-mass spectrometry (LC-MRM-MS) 📊 for precise biomolecular quantification. His contributions are crucial in drug discovery 🏥, gene editing 🧬, and biopharmaceutical development 💉. His expertise bridges biotechnology 🔬 and analytical methodologies 📈, advancing innovations in therapeutic monitoring and molecular diagnostics 🏥.

Publication Top Notes

Quantitative Analysis of Phosphorothioate Isomers in CRISPR sgRNA at Single-Residue Resolution Using Endonuclease Digestion Coupled with Liquid Chromatography Cyclic Ion Mobility Mass Spectrometry (LC/cIMS)

Generic Enrichment Method for Liquid Chromatography-Multiple Reaction Monitoring-Mass Spectrometry Assay for Quantitative Measurement of Biological Therapeutics in Serum